Skip to main content
Clinical Trials/NCT02068287
NCT02068287
Unknown
Phase 2

Anti-inflammatory and Cardiac Effects of Esmolol in Septic Shock. ESMOSEPSIS Study

Central Hospital, Nancy, France1 site in 1 country25 target enrollmentDecember 2013
ConditionsSeptic Shock
InterventionsEsmolol
DrugsEsmolol

Overview

Phase
Phase 2
Intervention
Esmolol
Conditions
Septic Shock
Sponsor
Central Hospital, Nancy, France
Enrollment
25
Locations
1
Primary Endpoint
Hemodynamic effects of Esmolol in septic shock patients (Value of cardiac index l/min/m2)
Last Updated
10 years ago

Overview

Brief Summary

Beta adrenergic system, over-activated in septic shock patients, is a key modulator of the inflammatory response. Experimental works demonstrated that Esmolol, an highly selective beta-1 blocker, reduces heart rate and regulates the inflammatory response. A recent mono centric, double blind, randomized clinical work in septic shock patients has shown that Esmolol administration is safe and reduces effectively heart rate. However there are only sparse data on 1) regional and micro-circulation, 2) inflammation modulation in human resuscitated septic shock patients treated by esmolol.

Registry
clinicaltrials.gov
Start Date
December 2013
End Date
June 2017
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Central Hospital, Nancy, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • septic shock patients following the definition of the Surviving Sepsis Campaign
  • femoral and central venous catheters for thermodilution monitoring
  • fluid optimization
  • with a cardiac index \> 3 l/min/m2
  • Heart Rate \>100 /min

Exclusion Criteria

  • Cardiogenic shock
  • Bradycardia
  • History of Severe Asthma
  • Indications against esmolol

Arms & Interventions

ESMOLOL

Resuscitated, hyperkinetic septic shock patients are treated with esmolol in order to reduce heart rate of 20% during 6 hours. During the intervention period, multimodal macro and micro hemodynamic data are recorded.

Intervention: Esmolol

Outcomes

Primary Outcomes

Hemodynamic effects of Esmolol in septic shock patients (Value of cardiac index l/min/m2)

Time Frame: Before administration (H0) and each hour (H1-H2-H3-H4-H5-H6) during the whole administration period and one hour after Esmolol cessation (H7)

Compare, in septic shock patients, the mean cardiac index before and after administration of Esmolol.

Secondary Outcomes

  • Effects on vasopressor requirement (amount of norepinephrine infused in microgram/kg) during Esmolol administration(Record of each change in vasopressor dosage to maintain a mean arterial pressure at 70 mmHg during the whole Esmolol administration period (H0 to H6) and one hour after esmolol cessation (H7))
  • Microcirculatory and regional circulation effects of Esmolol in septic shock patient(Before (H0), 6 hours after Esmolol introduction (H6) and 1 hour after esmolol cessation (H7))
  • Changes in the Cytokine pattern(pro and anti inflammatory cytokines assay) induced by Esmolol administration in septic shock patients(Before administration of Esmolol (H0) and 6 hours after introduction of Esmolol (H6))
  • Description of the cardiac function during Esmolol Administration in septic shock patients(Before administration (H0), at 4 hours, 6 hours after introduction and 1 hours after esmolol cessation)

Study Sites (1)

Loading locations...

Similar Trials